

1 **Interaction of BIR2/3 of XIAP with E2F1/Sp1 Activates MMP2 and Bladder Cancer**
2 **Invasion by Inhibiting Src Translation**

3

4 **Jiheng Xu^{1,2}, Honglei Jin¹, Jingxia Li², Junlan Zhu², Xiaohui Hua^{1,2}, Zhongxian Tian^{1,2},**
5 **Maowen Huang^{1,2}, Rui Yang², Haishan Huang^{1,*} and Chuanshu Huang^{2,*}**

6

7 ¹School of Laboratory Medicine and Life Science, Wenzhou Medical University,
8 Wenzhou, Zhejiang, 325035, China

9 ²Nelson Institute of Environmental Medicine, New York University School of Medicine,
10 Tuxedo, NY 10987, USA

11

12

13

14 **Running title:** XIAP BIR2/3 promotes bladder cancer invasion

15

16

17 *** Corresponding author:**

18 Haishan Huang, Ph.D. School of Laboratory Medicine and Life Science, Wenzhou Medical
19 University, Wenzhou, Zhejiang, China 325035; E-mail: haishan_333@163.com;

20 Chuanshu.huang@nyumc.org;

21

22

23

24

25

26

27

28 **Abstract**

29 Although X-linked inhibitor of apoptosis protein (XIAP) is associated with cancer cell
30 behaviors, the structure-based function of XIAP in promotion human bladder cancer (BC)
31 invasion is barely explored. Herein, we discovered that ectopic expression of the BIR
32 domains of XIAP rescued the MMP2 activation and invasion in XIAP-deleted BC cells,
33 while Src was further defined as a XIAP downstream negative regulator for MMP2 activation
34 and BC invasion. The inhibition of Src expression by BIR domains was caused by attenuation
35 of Src protein translation upon miR-203 upregulation resulting from direct interaction of
36 BIR2 and BIR3 with E2F1 and Sp1, consequently leading to fully activation of E2F1/Sp1.
37 Our findings provide a novel insight into understanding of specific function of BIR2 and
38 BIR3 of XIAP in BC invasion, which will be highly significant for the design/synthesis of
39 new BIR2/BIR3-based compounds for invasive BC treatment.

40

41 **Key words:** BIR domains of XIAP/Invasion/E2F1/Sp1/Src

42

43 **Introduction**

44 X-linked inhibitor of apoptosis (XIAP) is an IAP protein family member and a
45 well-defined inhibitor of the caspase/apoptosis pathway [1-3]. Emerging evidence has
46 revealed that abnormal expression of XIAP is associated with tumorigenesis in breast cancer
47 [4], prostate cancer [5-7], acute and chronic leukemia [8-10], bladder cancer [11] and other
48 types of cancers [12,13]. It is notable that XIAP overexpression is particularly associated
49 with the progression and aggression of malignant cancer [14,15]. Thus, XIAP is widely
50 considered as an important player in cancer development and malignancy behaviors.

51 There are four functional domains in XIAP: three repeats of the baculovirus IAP repeat
52 (BIR) domain at its NH₂ terminus and a RING finger domain near its COOH terminus. The
53 formers are mainly responsible for its anti-apoptotic function by inhibiting caspase-3, -7 and
54 -9, and the latter contains E3 ubiquitin ligase activity, allows IAPs to ubiquitinate themselves,
55 caspase-3, and caspase-7 *via* the proteasome-dependent mechanism [16]. The studies from
56 our laboratory and others reveal novel functions of XIAP beyond anti-apoptotic function
57 [17-19]. For example, XIAP upregulates cyclin D1 expression *via* an E3 ligase-mediated
58 protein phosphatase 2A/c-Jun axis [20] and upregulates cyclin E expression as a result of
59 direct binding of E2F1 by the BIR domains, which promotes human colon cancer cell growth
60 [21]. XIAP also enhances human invasive BC cell proliferation due to the BIR
61 domain-mediated *c-Jun/miR-200a/EGFR* axis [22]. The RING domain of XIAP interacts
62 with RhoGDP dissociation inhibitor α protein to inhibit RhoGDI α SUMOylation at Lys-138,
63 subsequently affecting human colon cancer cell motility [23,24]. Moreover, downregulation
64 of the tumor suppressor p63 α protein expression by the RING domain of XIAP promotes
65 malignant transformation of bladder epithelial cells [25]. Thus, although XIAP was originally
66 classified as an inhibitor of apoptosis protein family member, the function of XIAP on cancer
67 cell proliferation, motility and transformation and its signaling pathway have attracted a great
68 deal of attention.

69 Our recent preliminary study emphasizes the novel role of XIAP on BC cancer
70 invasion and reveals that XIAP promotes bladder cancer invasion through its BIR domains,

71 indicating a previously underappreciated role of BIR domains to promote invasive activity of
72 cancer cells. Thus, we further dissected the signaling pathways related to this important
73 function in the current study. We discovered that this novel function is mediated by specific
74 activating MMP2 due to BIR domain-initiated suppression of Src protein translation.
75 Moreover, the BIR domains of XIAP attenuated Src protein translation due to directly
76 interaction of BIR2 and BIR3 with E2F1 and Sp1, respectively, leading to miR-203
77 transcription, and its binding to Src mRNA 3'-UTR region.

78

79

80

81 **Results**

82

83 **XIAP BIR domains specifically promoted MMP2 activation and BC invasion in human** 84 **BC cells.**

85 XIAP contains three repeat BIR domains in the N terminus and one RING domain in
86 the C terminus as schematically shown in Figure 1A. To uncover the potential role of these
87 domains in mediation of human high invasive BC behaviors, we employed two human
88 invasive BC cancer cell lines, UMUC3 and T24T. As shown in Figure 1B, inhibition of XIAP
89 expression by its specific shRNA resulted in a profound specific decrease in MMP2
90 activation without affecting pro-MMP2 protein in T24T cells. Unexpectedly, the reduction of
91 MMP2 activation was further reversed by ectopic expression of HA- Δ RING (XIAP in the
92 absence of all three BIR domains), but not reversed by ectopic expression of HA- Δ BIR
93 (XIAP in the absence of RING domain). A similar result was also observed in UMUC3 cells
94 (Figure 1C). These findings indicate that the BIR domains but not the RING domain were
95 crucial for XIAP-mediated MMP2 activation in human BC cells.

96 MMP2 degrades cellular matrix components and the basement membrane, and
97 therefore reduces the barriers for cancer cell migration and/or invasion [26]. Therefore, we
98 next determine the capacity of cell migration and invasion of XIAP BIR domains in T24T

99 cells. As shown in Figures 1D and 1E, inhibition of XIAP expression dramatically reduced
100 BC cell invasion, which is consistent with the reduced activated MMP2 level (Figures 1B and
101 1C). The reduction of BC cell invasion was restored when ectopic expression of Δ RING
102 (Figures 1D and 1E), indicating that BIR domains are crucial for XIAP-mediated BC
103 invasion. Interestingly, inhibition of XIAP expression increased cell migration (Figures 1D
104 and 1E), suggesting that although cancer cell invasion and migration are appealingly linked in
105 many experimental system, but may be divergent in the significance and mechanism in
106 human BC cells as shown in our recently studies [27].

107

108 **Src tyrosine kinase protein expression was inhibited by XIAP BIR domains in BC cells**
109 **and was downregulated in human and mouse BCs.**

110 It has been reported that decreased Src protein expression is associated with late-stage
111 bladder tumor progression [28]. Thus, we tested whether different domains of XIAP could
112 regulate the expression of Src in BC cells. As shown in Figure 2A, attenuation of XIAP
113 expression resulted in a profound increase in Src protein expression and this augmentation on
114 Src protein expression was reversed by ectopic expression of HA- Δ RING, but not by
115 HA- Δ BIR. This result indicates that the BIR domains but not the RING domain are crucial
116 for XIAP inhibition of Src protein expression.

117 Next, we corroborated the negative association of Src protein expression and the stage
118 of bladder cancer using both clinical samples and an *in vivo* animal model. Thus, we
119 evaluated Src expression in 20 pairs of human BC tissues and their adjacent appealingly
120 normal bladder tissues that had been surgically removed from patients diagnosed with BCs.
121 As shown in Figure 2B, a profound reduction in src mRNA expression was observed in
122 human BC tissues, with an overall average of a 3-fold lower relative src mRNA level in
123 comparison with the normal controls. Consistent with the mRNA expression results,
124 significantly decreased Src protein expression was also observed in human invasive bladder
125 cancer tissues (Figure 2C). Moreover, we determined the expression of Src in a mouse model
126 of bladder cancer via consistent exposure of mice to N-butyl-N-(4-hydroxybutyl)-nitrosamine

127 (BBN) for 20 weeks. As illustrated in Figures 2D and 2E, the results from the
128 immunohistochemistry (IHC) staining revealed that Src expression was markedly decreased
129 in mouse invasive BC tissues in comparison to normal mouse bladder tissues. Thus, the
130 reduced expression of Src in invasive bladder cancer and its increase following XIAP
131 depletion indicate the negative correlation between Src and XIAP expression in BCs.

132

133 **XIAP BIR domains-mediated Src downregulation was critical for BC cell invasion.**

134 To test association of Src suppression by BIR domain with BC invasion, Src was either
135 knocked down or overexpressed in T24T deficient cells, T24T (shXIAP). As shown in
136 Figures 2F and 2G, knockdown of Src in T24T (shXIAP) cells resulted in a greater invasion
137 ability as compared with its nonsense transfectant (Figures 2H & 2I), indicating that Src is a
138 XIAP downstream target and its downregulation is responsible for the XIAP-mediated BC
139 cell invasion. Expectedly, overexpression of Src in T24T (Δ RING) cells attenuated cell
140 invasion in comparison to scramble vector transfectant (Figures 2J and 2K). Our results
141 reveal that Src suppression participates into the XIAP BIR domains-mediated BC cell
142 invasion.

143

144 **XIAP BIR domains inhibited Src protein translation through upregulating miR-203 in** 145 **human BC cells.**

146 Our above results showed that the deletion of XIAP BIR domains increased Src protein
147 expression (Figure 3D), indicating that XIAP BIR domains mediate Src inhibition. Therefore,
148 we next determined whether the XIAP BIR domains have a suppressive effect on Src mRNA
149 expression. The results showed that src mRNA levels were nearly comparable in T24T cells
150 with XIAP knockdown, or XIAP knockdown with either BIR domain overexpression or
151 RING domain overexpression (Figure 3A). Similar results were also observed in UMUC3
152 cells with similar approaches (Figure 3B). Interestingly, depletion of XIAP expression in
153 T24T cells resulted in a faster degradation of Src protein (Figure 3C), indicating that XIAP
154 plays a role in Src protein stabilization, further suggesting that XIAP might regulate Src

155 protein translation. The results from incorporation of 35S-methionine/ cysteine into newly
156 synthesized Src protein in T24T cells in XIAP knockdown cells was markedly increased in
157 comparison to control T24T(nonsense) cells (Figure 3D), further revealing that XIAP did
158 inhibit Src protein translation. Finally, we found that ribosomal S6 appears not related to
159 XIAP-mediated suppression of Src protein translation.

160 To explore the mechanisms underlying XIAP suppression of Src protein translation,
161 the potential effect of XIAP on phosphorylation of S6 ribosomal protein was evaluated, and
162 the results showed that phosphorylation of S6 ribosomal protein was comparable in
163 T24T(Nonsense) and T24T(shXIAP) cells (Figure 3E), excluding the possible involvement of
164 S6 ribosomal protein in XIAP inhibition of Src protein translation. We next tested whether
165 XIAP modulated Src mRNA 3'-UTR activity and the results indicated that XIAP knockdown
166 resulted in the augmentation on Src mRNA 3'-UTR activity, whereas ectopic expression of
167 three BIR domains (HA- Δ RING) reversed an increase in Src mRNA 3'-UTR activity (Figure
168 3F), suggesting that the BIR domains are required for XIAP inhibition of src mRNA 3'-UTR
169 activity. Since microRNAs (miRNAs) could inhibit protein translation *via* interacting mRNA
170 3'-UTRs [29], a bioinformatics analysis was conducted and showed that miR-141, miR-144,
171 miR-137, miR-203, miR-200a, and miR-503 are putative miRNAs that can bind to the
172 3'-UTR region of Src mRNA (Table 1). The results for evaluation of these putative miRNAs
173 indicated that knockdown of XIAP only attenuated miR-203 expression in T24T cells (Figure
174 3G), and the reduction on miR-203 expression was further reversed by ectopic expression of
175 XIAP in the absence of the BIR domains (Figure 3H), indicating that the BIR domains
176 specifically inhibit miR-203 expression in human BC cells. Moreover, the point mutations of
177 the miR-203 binding site in the Src mRNA 3'-UTR reporter completely abolished the
178 increased luciferase activity due to XIAP knockdown in T24T cells (Figures 3I & 3J),
179 revealing that miR-203 binding site is crucial for XIAP/BIR inhibition of Src mRNA 3'-UTR
180 activity. This notion was great supported by the results obtained in T24T (shXIAP/ Δ RING) in
181 comparison to that in T24T (shXIAP/Vector) cells (Figure 3K). These results reveal that
182 miR-203 directly binds to 3'-UTR of Src mRNA and mediates the BIR domains inhibition of

183 Src protein translation. To unravel the role of miR-203 in regulation of Src protein expression,
184 miR-203 was transfected into T24T (shXIAP) and UNUC3 (shXIAP) cells. As shown in
185 figure 3L and 3M, overexpression of miR-203 abolished Src protein expression in both T24T
186 (shXIAP) and UNUC3 (shXIAP) cells, indicating that miR-203 inhibits Src protein
187 expression. Collectively, our study demonstrates that the XIAP BIR domains promote
188 miR-203 expression, resulting in an increase in miR-203 interacting with the src mRNA
189 3'-UTR and in turn inhibiting Src protein translation.

190

191 **XIAP BIR domains promoted miR-203 transcription through activation of E2F1 and**
192 **Sp1.**

193 Since miRNAs possess differential stability in human cells [30], the effect of
194 XIAP/BIR on miR-203 stability were evaluated. As shown in Figure 4A, neither inhibition of
195 XIAP expression nor ectopic expression of HA- Δ RING in T24T (shXIAP) cells showed a
196 significant regulatory effect on miR-203 stability as compared with control transfectants.
197 Pre-miRNAs are regulated at transcription and are processed to mature miRNAs by enzymes,
198 such as dicer and argonaute 2 [31,32]. To examine whether the BIR domains of XIAP
199 regulate miR-203 at transcriptional level, we determined the effect of XIAP and its BIR
200 domains on pre-miR-203 expression as well as its promoter activity. The results showed that
201 both pre-miR-203 abundance and its promoter-driven luciferase reporter activity were
202 impaired in XIAP knockdown cells, whereas ectopic expression of Δ RING domains restored
203 both pre-miR-203 expression and its promoter activity (Figures 4B & 4C). These results
204 strongly suggest that BIR domains promote miR-203 transcription. It is reported that
205 promoter region demethylation is involved in upregulation of miR-203 [33]. Thus, we tested
206 whether promotion of miR-203 transcription was due to the regulatory effect of BIR domain
207 on demethylation of miR-203 differentially methylated region (DMR). As shown in Figure
208 4D, there was no any observable alteration of methylation and unmethylation between T24T
209 cells with either XIAP knockdown cells, or Δ RING domain overexpressed cells, in
210 comparison to parental T24T cells, suggesting that promotion of miR-203 transcription by

211 BIR domains is not through affecting demethylation of miR-203 promoter region. We next
212 bioinformatically analyzed the potential transcription factor binding sites in miR-203
213 promoter region, and the results revealed that the promoter contains binding sites for multiple
214 transcription factors, including c-Jun, E2F1, Sp1, ELK1, and NF κ B (Figure 4E). The effect
215 of XIAP on these transcription factor expressions was explored in T24T (nonsense) and T24T
216 (shXIAP) cells. The results indicated that knockdown of XIAP in T24T cells only attenuated
217 E2F1 expression, no effect on Sp1 expression and increased p65 and c-Jun (Figure 4F).
218 However, depletion of XIAP expression in T24T cells dramatically inhibited both E2F1- and
219 Sp1-dependent transcription activity, which could be completely reversed by ectopic
220 expression of Δ RING domain (Figures 4G & 4H). These results suggest that Inhibition of
221 E2F1- and Sp1-dependent transcription activity might be associated with BIR domain
222 attenuation of miR-203 transcription.

223 To gain direct evidence for the transactivation of the miR-203 promoter by Sp1 and
224 E2F1, a chromatin immunoprecipitation (ChIP) assay was employed to test the potential
225 directly interaction of Sp1 and E2F1 to their putative binding sites in miR-203 promoter
226 region. As shown in Figure 4I, Sp1 did show its binding activity to miR-203 promoter at
227 -489bp, whereas E2F1 was only be able to bind at site -439bp, but not putative binding site at
228 -194 bp of the miR-203 promoter region (Figure 4I). Moreover, overexpression of E2F1
229 remarkably increased miR-203 expression but did not affect Sp1 expression in both T24T
230 (shXIAP/vector) and UMUC3 (shXIAP/vector) cells (Figures 4J & 4K), while knockdown of
231 Sp1 not only attenuated miR-203 expression activity in T24T cells (Figure 4L & 4M), but
232 also inhibited E2F1 protein expression in T24T cells (Figure 4L). Consistent with E2F1 and
233 Sp1 promotion of miR-203 transcription, ectopic expression of E2F1 in XIAP knockdown
234 cells increased miR-203 promoter activity (Figure 4N), while knockdown of Sp1 significantly
235 decreased miR-203 promoter activity (Figure 4O). These results reveal that both Sp1 and
236 E2F1 play role in XIAP promotion of miR-203 transcription and induction in human BC cells,
237 and Sp1 also acts as upstream regulator of E2F1 to form a positive loop for promoting
238 miR-203 transcription in addition to its direct regulation of miR-203 induction.

239

240 **Sp1 is crucial for BIR domains promoting E2F1 transcription and BC cell invasion.**

241 We further examined the mechanism of E2F1 upregulation by XIAP. The results
242 showed that knockdown of XIAP expression greatly reduced the mRNA level of E2F1 in
243 both T24T and UMUC3 cells (Figures 5A and 5B). Moreover, depletion of XIAP or Sp1
244 greatly decreased E2F1 promoter activity, whereas the reduction on E2F1 promoter activity
245 could completely reversed by ectopic expression of Δ RING domain (Figure 5C), strongly
246 indicating that XIAP BIR domains upregulate E2F1 at the transcription level in Sp1
247 dependent manner. The Sp1 promotion of E2F1 transcription was also supported by the result
248 from a bioinformatics analysis showing that there are three potential binding sites for Sp1 in
249 the E2F1 promoter region (Figure 5D). Consistent with crucial roles of Sp1 and E2F1 in
250 modulation of miR-203 transcription, overexpression of E2F1 in T24T (shXIAP) cells
251 markedly increased the cancer cell invasion, while knockdown of Sp1 in T24T cells
252 significantly inhibited the cancer cell invasion (Figure 5E-5H).

253

254 **BIR2 and BIR3 specifically interacted with E2F1 and Sp1, respectively, to coordinately**
255 **promote BC invasion.**

256 To further elucidate the mechanism of XIAP regulation of Sp1 and E2F1
257 transcriptional activity, we tested the possibility that the XIAP interacts with Sp1. The results
258 from immunoprecipitation (IP) assay by using T24T cells that expressed HA-XIAP with or
259 without GFP-Sp1. Intriguingly, HA-tagged XIAP and E2F1 was present in the
260 immunoprecipitates following anti-GFP antibodies pulling down of GFP-tagged Sp1 (Figure
261 6A). This physical interaction was further demonstrated in the immunoprecipitates using
262 anti-HA antibodies pulling down of HA-XIAP (Figure 6B). More interesting is that both Sp1
263 and E2F1 proteins were present in the co-precipitated protein complex in T24T cells in the
264 absence of XIAP RING domain but not detectable in T24T cells in the absence of XIAP BIR
265 domains (Figure 6C), indicating that XIAP interacts with Sp1 and E2F1 through BIR
266 domains in BC cells. Since that XIAP contains three BIR domains, we further determine

267 whether Sp1 or E2F1 interacts with XIAP through specific BIR domain. The results from
268 co-immunoprecipitation assays using anti-HA antibodies demonstrated that BIR2 domain
269 specially interacted with E2F1, while Sp1 specifically bound to BIR3 domain (Figure 6D). To
270 further investigate the physiological consequence of this physical interaction between Sp1
271 and XIAP or E2F1 and XIAP in cells upon serum stimulation, we incubated T24T(HA-XIAP)
272 cells in medium containing 20% FBS for 30 min, and the cell extracts were used to perform
273 co-immunoprecipitation assay to pull down endogenous Sp1 and E2F1 by using anti-HA
274 antibodies. The results showed that serum stimulation led to a substantial decrease in XIAP
275 interaction with both Sp1 or E2F1 proteins in BC cells (Figure 6E). Given that pre-miR-203
276 transcription occurs in the nucleus, we anticipated that the serum stimulation might result in
277 dissociation of XIAP from E2F1 and Sp1 in BC cells. To test this notion, cytoplasmic and
278 nuclear fractions from T24T cells upon serum stimulation were isolated and further subjected
279 to immunoblotting analysis. As shown in Figure 6F, nuclear XIAP translocated to the
280 cytoplasmic upon 20% FBS stimulation, but E2F1 and Sp1 still stayed in nuclear, indicating
281 that nuclear XIAP are mainly responsible for XIAP interaction with Sp1 and E2F1.
282 Furthermore, ectopic expression of BIR2 and BIR3 showed restoration of Src inhibition and
283 MMP2 activation (Figure 6G) and rescued invasion ability (Figures 6H and 6I) in
284 XIAP-deletion BC cells. Consistent with BIR3 promotion of E2F1 transcription *via* Sp1, only
285 ectopic expression of BIR3, but not BIR2, rescued E2F1 protein expression (Figure 6G).
286 Given that our published study indicates the inhibition of Rac1 expression by XIAP [34], it is
287 interesting to define which BIR domain is associated with this function. The results revealed
288 that Rac1 upregulation in XIAP-deficient cells could be specifically abolished by ectopic
289 expression of BIR1, but not either BIR2 or BIR3 (Figure 6G), suggesting that BIR1 mediates
290 XIAP inhibition of Rac1 expression. Consistent with activation of MMP2 by BIR2 and BIR3,
291 ectopic expression of BIR2 and BIR3 also restored E2F1- and Sp1-dependent transactivation
292 (Figures 6J and 6K), miR-203 promoter activation, as well as miR-203 expression (Figures
293 6L and 6M). These results demonstrate that the crosstalk of BIR2 and BIR3 by interaction

294 with E2F1 and Sp1 are drive force for activation of E2F1 and Sp1 leading to miR-203
295 transcription, Src protein translation inhibition, MMP2 activation and BC invasion.

296

297 **Discussion**

298 Our current study discovered that the BIR domains of XIAP is one of the major factors
299 that promote human BC cell invasion. This important function of XIAP/BIR domains is
300 mediated *via* specific activating MMP2 in Src protein inhibition-dependent manner. Further
301 studies revealed that the BIR domains initiate Sp1- and E2F1-mediated transcription of
302 miR-203, which is able to bind the 3'-UTR of src mRNA and ultimately to block Src protein
303 translation. We also identified that activated Sp1 by BIR3 also acts as transcription factor to
304 positively regulation of E2F1 transcription. Most interestingly, the BIR2 is found to specific
305 bind to E2F1, while BIR3 interacts with Sp1 in intact BC cells, and those protein-protein
306 interactions as well as SP1 positively modulation of E2F1 result in ultimately activation of
307 E2F1 and Sp1, and in turn lead to miR-203 transcription, Src protein translation inhibition,
308 and consequently activate MMP2 and BC invasion. This novel mechanistic discovery of
309 BIR2 and BIR3 domains of XIAP in human BC invasion provides highly significant insight
310 into understanding of XIAP in BC invasion.

311 Matrix metalloproteinases-2 (MMP2) belongs to one of the gelatinases that are primary
312 subgroups of MMPs on the premise of domain structure [35]. MMP2 has a well-known role
313 in degradation of connective tissue stroma and basement membranes, and is a good candidate
314 for a biological marker in many cancers [36]. MMP2 is secreted into the matrix as
315 pro-MMP2 with an auto-inhibitory N-terminal pro-domain [37]. The cysteine switch motif in
316 this domain blocks the catalytic zinc, preventing hydrolysis of substrates [38]. Pro-MMP2
317 could be activated *via* proteolytic cleavage or chemical disruption of the pro-domain to
318 expose the catalytic zinc for fully enzyme activity [39]. MMP2 activation has been reported
319 to be directly correlated with the aggressiveness of bladder tumors [40]. Here, we are the first
320 to unravel a novel function for XIAP in modulating MMP2 activation that is negatively
321 regulated by proto-oncogene tyrosine-protein kinase Src. We also demonstrate that the

322 crosstalk between BIR2 and BIR3 domains is crucial to inhibit Src protein translation through
323 directly targeting of its mRNA 3'UTR by upregulated miR-203, while the direct
324 protein-protein interactions of BIR2 and BIR3 with E2F1 and Sp1, together with crosstalk
325 between Sp1 and E2F1 result in their strong binding to promoter region of miR-203 leading
326 to its fully transcription, Src inhibition and MMP2 activation in human BC cells. These
327 findings establish a new bridge between XIAP overexpression and MMP2 activation in
328 human BC high invasion, and further help us better understanding XIAP induction associated
329 with the progression and aggression of malignant bladder tumor development [14,15].
330 Further investigation will be mainly focusing on the precise role of XIAP *in vivo* by using
331 XIAP knockout, or overexpression, as well as each BIR domain deletion knock-in mouse
332 model.

333 The function of Src in cancer biology in general is dependent on the cancer types. For
334 example, Src is overexpressed or activated in breast, prostate, colorectal, pancreatic,
335 hepatocellular, esophageal, head and neck, ovarian, and lung cancer as well as in leukemia
336 and lymphoma [41]. Src is the oldest and best-studied proto-oncogene, and its high
337 expression or activation is positively associated with tumor grade and stage in these cancers
338 [42-44]. However, the divergence of the expression and activity of Src are reported in bladder
339 cancers. It has been reported that the Src expression level and activity are surprisingly low in
340 human BC cell lines including TccSup, T24, and U5637 [45]. Moreover, compared with
341 high-grade counterparts, low-grade BC cell lines and tumors possess high expression and
342 activity of Src [46]. Src protein levels are also attenuated with increasing bladder cancer stage
343 and affected cancer metastasis [28,47]. Our current study revealed low mRNA and protein
344 expression of Src in human and mouse BC tissues. Thus, the studies from our laboratory and
345 others suggest that Src is a potential tumor suppressor in BCs. To the best of our knowledge,
346 we unprecedented discover that Src-mediated BC invasion mainly rely on its downstream
347 powerful BC invasion/metastatic effector, MMP2. We also demonstrate that Src-associated
348 MMP2 regulation only target MMP2 activation rather than its expression in BIR domains of
349 XIAP-dependent. These new findings not only help us be more aware of the tumor

350 suppressive role of Src in BCs, but also warn us to consider the tissue-specificity of drugs
351 targeting Src. Further study need to be elucidated about how Src-regulated MMP2 activation
352 in our future endeavors.

353 It has previously been reported that miR-203 is significantly upregulated in bladder
354 cancers [48], indicating that it may function as a tumor promoter in the disease progression.
355 In the present studies, we found that miR-203 had an essential role in XIAP regulation of Src
356 expression *via* binding to 3'-UTR of Src mRNA. Consistent with its oncogenic role of XIAP
357 in Src protein expression, we found that miR-203 significantly inhibited Src protein
358 translation without affecting its mRNA. Furthermore, we showed that XIAP promoted
359 miR-miR-203 expression through enhancing Sp1 and E2F1 activation. Sp1 and E2F1 are
360 both transcription factors, and their expression and activity has been reported to be elevated
361 in many cancers [49,50]. We reported here that XIAP might act as a promising natural
362 promoter of Sp1 and E2F1 through specially interacting with them and enhancing their
363 activity. Moreover, we found that Sp1 or E2F1 was mainly bound to nuclear XIAP in
364 unstimulated BC cells, but dissociated with XIAP resulting from nuclear XIAP shuttled to
365 cytoplasm following serum stimulation. Additionally, the molecular mechanism that mediates
366 the dissociation of Sp1 and E2F1 from XIAP in BC cells upon serum stimulation also merits
367 further investigation. Our previous report reveals that in HCT116 colon cancer cells, the BIR
368 domains of XIAP could bind E2F1 to promote cell growth by strengthening cyclin E
369 expression [21]. Our current finding further extends this knowledge revealing that E2F1
370 binds to XIAP BIR2 domain and made a new discovery of Sp1 interaction with XIAP BIR3
371 domain, and Sp1 also acts as an E2F1 upstream transcriptional factor to initiate a crosstalk
372 with E2F1 to promote BC cell invasion. The crosstalk between BIR2 and BIR3 domains in
373 regulation of miR-203/SRC/MMP2 axis is greatly supported by the findings that ectopic
374 expression of either BIR2 or BIR3 could restore E2F1-dependent transactivity, whereas only
375 BIR3, but not BIR2, rescued Sp1-dependent transactivity. Consistently, the defect of
376 miR-203 promoter-driven reporter activity and miR-203 expression in XIAP knockdown
377 cells could be completely restored by ectopic expression of either BIR2 or BIR3. These

378 results suggesting that Sp1 acts as an E2F1 upstream regulator for XIAP promotion of MMP2
379 activation and invasion of BC cells.

380 In summary, our studies have revealed a novel Sp1/E2F1/miR-203/Src pathway that is
381 responsible for activation of MMP2 and the tumor-promotive role of XIAP in BC cell
382 invasion. We show a new link between XIAP, Src and MMP2 activation, which may be BC
383 specificity. More importantly, we identify two physical protein-protein interactions: XIAP
384 and Sp1, XIAP and E2F1, and further point out that BIR2 domain of XIAP is essential and
385 sufficient for its interaction with E2F1, while BIR3 domain of XIAP is mainly responsible for
386 its binding with Sp1. In addition, we find that BIR3 of XIAP-initiated Sp1 also acts as an
387 upstream regulator for E2F1 transcription. Collectively, our findings from current studies, for
388 the first time to the best of our knowledge, demonstrate an essential role of crosstalk between
389 BIR2 and BIR3 of XIAP by their interactions with E2F1 and Sp1, respectively, to activate
390 MMP2 and BC invasion by inhibiting Src protein translation in miR-203-dependent manner.
391 Our findings provide novel molecular evidence that contributes to an improved understanding
392 of the tumor-suppressive role of Src and its relationship with the BIR domain of XIAP and
393 MMP2 activation in bladder cancer cells, suggesting that Src or the BIR domains of XIAP
394 could potentially be used as a therapeutic target in future BC therapy. Finally, these findings
395 also provide a clue for us to understand the reason that high nuclear expression of XIAP is
396 associated with poor clinical outcome of cancer patients that is observed in clinical studies
397 [51].

398

399 **Materials and methods**

400

401 **Cell lines, plasmids, antibodies, and other reagents.**

402 The human invasive BC cell line UMUC3 was provided by Dr. Xue-Ru Wu
403 (Department of Urology and Pathology, New York University School of Medicine, New
404 York, NY), and was used in our previous studies [52]. The human metastatic BC cell line
405 T24T, which is a lineage-related metastatic lung variant of the invasive BC cell line T24 [53],

406 was kindly provided by Dr. Dan Theodorescu [54] and used in our previous studies [55].
407 UMUC3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)
408 supplemented with 10% FBS (HyClone, Logan, UT), 1% penicillin/streptomycin and 2 mM
409 L-glutamine (Life Technologies, Rockville, MD). T24T cells were cultured in DMEM/Ham's
410 F-12 (1:1 volume) mixed medium supplemented with 5% FBS, 1% penicillin/streptomycin
411 and 2 mM L-glutamine. The shRNA that specifically targets human XIAP and Sp1 was
412 purchased from Open Biosystems (GE, Pittsburgh, PA). HA- Δ BIR and HA- Δ RING
413 expression plasmids were described in our previously studies [20,21,25]. miR-203 mimic
414 RNA was kindly provided by Dr. Dale D. Tang (The Center for Cardiovascular Sciences,
415 Albany Medical College, Albany, New York) [56]. The Src expression plasmid was obtained
416 from Addgene (Cambridge, MA). E2F1- and Sp1-dependent luciferase reporters were
417 described in our previous papers [25,57]. The human Src mRNA 3'-UTR luciferase reporters
418 and its mutant (the binding site of miR-203 was mutated) were cloned into a pMIR-report
419 luciferase vector. The plasmid containing the luciferase reporter under control of human
420 miR-203 gene promoter was constructed into a PGL3-BASIC vector. Anti-XIAP antibody
421 was purchased from Becton, Dickinson and Company (Franklin Lakes, NJ). Specific
422 antibodies against HA, Src, S6 ribosomal protein, P-S6 ribosomal protein Ser235/236, p53,
423 c-Jun, P-c-Jun at Ser73, NF- κ B p65 and GAPDH were purchased from Cell Signaling
424 Technology (Beverly, MA). Antibodies specific for Sp1, E2F1, MMP2 and β -Actin, were
425 bought from Santa Cruz (Dallas, TX). Antibodies specific against p50 were bought from
426 Abcam (Cambridge, MA, USA). The protein synthesis inhibitor cycloheximide (CHX) was
427 purchased from Calbiochem (San Diego, CA, USA). The dual luciferase assay kit was
428 purchased from Promega (Madison, WI, USA). TRIzol reagent and the SuperScript™
429 First-Strand Synthesis system were bought from Invitrogen (Grand Island, NY, USA).
430 PolyJet™ DNA In Vitro Transfection Reagent was purchased from SignaGen Laboratories
431 (Rockville, MD, USA). Both the miRNeasy Mini Kit and the miScript PCR system for
432 miRNA detection were bought from Qiagen (Valencia, CA, USA).

433

434 **Human bladder cancer tissue samples.**

435 Twenty pairs of primary bladder cancer samples and their paired adjacent normal
436 bladder tissues were obtained from patients who underwent radical cystectomy at the
437 Department of Urology of the Union Hospital of Tongji Medical College (Wuhan, China)
438 between 2012 and 2013. All specimens were immediately snap-frozen in liquid nitrogen after
439 surgical removal. Histological and pathological diagnoses were confirmed, and the specimens
440 were classified by a certified clinical pathologist according to the 2004 World Health
441 Organization Consensus Classification and Staging System for bladder neoplasms. All
442 specimens were obtained with appropriate informed consent from the patients, and a
443 supportive grant was obtained from the Medical Ethics Committee of China. The experiments
444 were carried out in accordance with The Code of Ethics of the World Medical Association
445 (Declaration of Helsinki) for experiments involving human studies.

446

447 **Animal experiments and immunohistochemistry-paraffin (IHC-P).**

448 Male C57BL/6J mice at the age of 5~6 weeks were randomly divided into two groups,
449 with 12 mice in each group, including a vehicle-treated control group and an
450 N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-treated group. Mice in the BBN-treated
451 group received BBN (0.05%) in drinking water for 20 weeks, while vehicle-treated group
452 was provided with normal drinking water containing same amount of DMSO. The mice were
453 sacrificed at the end of the experiment and mouse bladder tissues were excised and fixed
454 overnight in 4% paraformaldehyde at 4°C. Fixed tissues were processed for paraffin
455 embedding, and the serial 5- μ m-thick sections were then immunostained with specific
456 antibodies against Src (Cell Signaling Technology). The resultant immunostaining images
457 were captured using an AxioVision Rel.4.6 computerized image analysis system (Carl Zeiss,
458 Oberkochen, Germany). Protein expression levels were presented by the integrated optical
459 density per stained area (IOD/area) that was analyzed with Image-Pro Plus version 6.0
460 (Media Cybernetics, MD). Briefly, the IHC stained sections were evaluated at 400-fold

461 magnifications, and at least 5 representative staining fields in each section were analyzed to
462 calculate the optical density based on typical images that had been captured.

463

464 **Western Blot.**

465 Western Blot were assessed as previously described [58]. Briefly, cells were plated in
466 6-well plates and cultured in normal FBS medium until 70–80% confluent. The cells were
467 then cultured in 0.1% FBS medium for 12 hours, followed by treatment with different doses
468 of ISO for the indicated time. The cells were washed once with ice-cold phosphate-buffered
469 saline, and cell lysates were prepared with a lysis buffer (10 mM Tris-HCl (pH 7.4), 1% SDS,
470 and 1 mM Na₃VO₄). An equal amount (80 µg) of total protein from each cell lysate was
471 subjected to Western blotting with the indicated antibody. Immunoreactive bands were
472 detected using alkaline phosphatase-linked secondary antibody and an ECF Western blotting
473 system (Amersham Biosciences, Piscataway, NJ). Images were acquired using a Typhoon
474 FLA 7000 imager (GE Healthcare, Pittsburgh, PA).

475

476 **RT-PCR and quantitative RT-PCR.**

477 Total RNA was extracted with TRIzol reagent (Invitrogen Corp. USA), and cDNAs
478 were synthesized with a SuperScript III First-Strand Synthesis System for RT-PCR
479 (Invitrogen Corp. USA). A pair of oligonucleotides (Forward:
480 5'-GATGATCTTGAGGCTGTTGTC-3' and Reverse:
481 5'-CAGGGCTGCTTTTAACTCTG-3') were used to amplify human GAPDH cDNA as a
482 loading control. The human Src cDNA fragments were amplified with a pair of human
483 Src-specific PCR primers (Forward: 5'-TCCGACTCCATCCAGGCTGA-3' and Reverse:
484 5'-TGTCCAGCTTGCGGATCTTG-3'). The human E2F1 cDNA fragments were amplified
485 with 5'-GAGGTGCTGAAGGTGCAGAA-3'; (Forward) and
486 5'-GTTTGCTCTTAAGGGAGATCTG-3' (Reverse). The PCR products were separated on 2%
487 agarose gels, stained with ethidium bromide (Fisher Scientific Corporation, USA), and
488 scanned for imaging under UV light. The results were visualized with a Alpha Innotech SP

489 Imaging System (Alpha Innotech Corporation, San Leandro, CA, USA). Quantitative
490 RT-PCR was performed to examine the expression level of mature miRNAs and pre-miRNA,
491 as described previously [59].

492

493 **[³⁵S] Methionine pulse new protein synthesis assays.**

494 Cells were incubated with methionine-cysteine free DMEM (Gibco-BRL, Grand Island,
495 NY, USA) containing 2% dialyzed fetal calf serum (Gibco-BRL) and 10 μM MG132 for 30
496 minutes and then incubated with 2% FBS methionine-cysteine-free DMEM containing
497 ³⁵S-labeled methionine/cysteine (250 μCi per dish, Biomedicals, Inc., Irvine, CA) for the
498 indicated periods. The cells were extracted with lysis buffer (Cell Signaling Technology)
499 containing a complete protein inhibitor mixture (Roche) on ice, and 500 mg of total lysate
500 was incubated with anti-Cyclin D1 antibody-conjugated agarose beads (R&D Systems,
501 Minneapolis, MN, USA) overnight at 4°C. The immunoprecipitates were washed with the
502 cell lysis buffer five times, heated at 100°C for 5 min and subjected to sodium dodecyl sulfate
503 polyacrylamide gel electrophoresis. The membranes were then subjected to autoradiography
504 for determination of the newly synthesized ³⁵S-labeled Cyclin D1 protein as described in our
505 previous studies[60].

506

507 **Luciferase assay.**

508 T24T and UMUC3 cells were transfected with the indicated luciferase reporter
509 construct in combination with a pRL-TK vector (Promega, Madison, WI). The transfectants
510 were seeded into 96-well plates and cultured for 12 hours. The cells were then extracted with
511 luciferase assay lysis buffer (Promega, Madison, WI) and subjected to determination of
512 luciferase activity using a luciferase assay system (Promega Corp., Madison, WI) with a
513 microplate luminometer LB 96V (Berthold GmbH & Co. KG, Bad Wildbad, Germany). The
514 luciferase activity was normalized to the internal control TK activity based on the
515 manufacturer's instructions.

516

517 **Methylation-specific PCR.**

518 Genomic DNA was isolated with a DNeasy Blood & Tissue Kit (Qiagen) according to
519 the manufacturer's instructions. Genomic DNA (2 mg) was treated with sodium bisulfite
520 using an EpiTect Bisulfite Kit (Qiagen). Methylation-specific PCR was performed using 20
521 ng of bisulfite-converted DNA and specific primers. Methylated primer and unmethylated
522 primers for the miR-203 promoter at the differentially methylated region (DMR) were
523 designed according to a previous study [61]. PCR products were run on a 2% agarose gel and
524 visualized after ethidium bromide staining. Bisulfite-converted methylated and unmethylated
525 DNA from the EpiTect PCR Control DNA Set (Qiagen) were used as positive and negative
526 controls.

527

528 **Immunoprecipitation.**

529 For immunoprecipitation experiments, cells transfected with the indicated plasmids
530 were collected and lysed in 1 × Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA,
531 USA) containing protease inhibitors (Roche, Branchburg, NJ, USA) followed by brief
532 sonication. Any insoluble material was removed by centrifugation at 16,000×g for 20 minutes
533 at 4°C. Immunoprecipitation was carried out by incubation of cell lysates with anti-HA or
534 anti-GFP antibody-conjugated agarose beads. After an overnight incubation, beads were
535 washed three times with immunoprecipitation lysis buffer, and bound proteins were subjected
536 to Western Blot assay [59].

537

538 ***In vitro* cell migration and invasion assays.**

539 *In vitro* migration and invasion assays were conducted using transwell chambers (for
540 migration assays) or transwell chambers pre-coated with Matrigel (for invasion assays)
541 according to the manufacturer's protocol (BD Biosciences, Bedford, MA), as described
542 previously [52]. Briefly, 700 µl of medium containing 10% FBS (for UMUC3 and T24T cells
543 with different transfectants) was added to the lower chambers, while homogeneous single cell
544 suspensions (5×10^4 cells/well) in 0.1% FBS medium as indicated were added to the upper

545 chambers. The transwell plates were incubated in a 5% CO₂ incubator at 37°C for 24 hours
546 and thereafter were washed with PBS, fixed with 4% formaldehyde, and stained with Giemsa
547 stain. The non-migrating or non-invading cells were scrapped off the top of the chamber. The
548 migration and invasion rates were quantified by counting the migratory and invasive cells in
549 at least five random fields under a light microscope (Olympus, Center Valley, PA).

550

551 **Statistical methods.**

552 Associations between categorical variables were assessed using a chi-square test.
553 Student's t-test was utilized to compare continuous variables, and the results are summarized
554 as the means \pm SD between different groups. Paired t-tests were performed to compare the
555 difference between paired tissues in the real-time PCR analysis. $p < 0.05$ was considered
556 statistically significant.

557

558 **Acknowledgement**

559 We thank Dr. Dale D. Tang from Albany Medical College for providing us with
560 miR-203 mimic RNA. This work was partially supported by the grants of NIH/NCI
561 CA165980, CA1776655 and CA112557, and NIH/NIEHS ES000260.

562

563 **Author contributions**

564 Conceptualization, J.H.X. and C.S.H.; Methodology, J.X.L., J.H.X., and H.L.J.; Investigation,
565 J.H.X., Z.X.T., X.H.H., J.L.Z., and M.W.H.; Writing – Original Draft, J.H.X. and C.S.H.;
566 Writing – Review & Editing, C.S.H. and H.S.H.; Funding Acquisition, C.S.H.; Resources,
567 H.S.H and C.S.H.; Supervision, R.Y., C.S.H., and H.S.H.

568

569 **Conflict of interest**

570 The authors declare no competing financial interests.

571

572 **References**

- 573 1. Green DR (2000) Apoptotic pathways: Paper wraps stone blunts scissors. *Cell* **102**: 1-4
- 574 2. Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during
- 575 cisplatin-induced apoptosis in human ovarian epithelial cancer cells. *Cancer research* **61**: 1862-1868
- 576 3. Eckelman BP, Salvesen GS, Scott FL (2006) Human inhibitor of apoptosis proteins: why XIAP is the black
- 577 sheep of the family. *EMBO reports* **7**: 988-994
- 578 4. Allensworth JL, Aird KM, Murray MB, Devi GR (2010) X-Linked Inhibitor of Apoptosis Protein (XIAP) Regulates
- 579 TRAIL-Induced Apoptosis in Inflammatory Breast Cancer Cells. *Cancer research* **70**:
- 580 5. Amantana A, London CA, Iversen PL, Devi GR (2004) X-linked inhibitor of apoptosis protein inhibition induces
- 581 apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. *Molecular cancer*
- 582 *therapeutics* **3**: 699-707
- 583 6. Devi GR (2004) XIAP as a target for therapeutic apoptosis in prostate cancer. *Drug News & Perspectives* **17**:
- 584 127-134
- 585 7. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV (2005) Increased
- 586 expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate
- 587 cancer metastasis precursor cells. *Cancer research* **65**: 2378-2386
- 588 8. Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS (2005) Sodium butyrate sensitizes human glioma cells to
- 589 TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
- 590 *Oncogene* **24**: 6877-6889
- 591 9. Akyurek N, Ren YS, Rassidakis GZ, Schlette EJ, Medeiros LJ (2006) Expression of inhibitor of apoptosis
- 592 proteins in B-cell non-Hodgkin and Hodgkin lymphomas. *Cancer* **107**: 1844-1851
- 593 10. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas N, Reed JC (2002) The mechanism of tumor cell
- 594 clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase
- 595 activation and apoptosis induction. *Blood* **99**: 1038-1043
- 596 11. Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, Li J, Tian Z, Jiang G, *et al.* (2018) XIAP overexpression promotes
- 597 bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta
- 598 mRNA stability. *Int J Cancer* **142**: 2040-2055
- 599 12. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A (2010) The inhibition of Bid expression by Akt
- 600 leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. *Oncogene* **29**: 5523-5536
- 601 13. Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA, Johnston PG, Longley DB (2009)
- 602 Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.
- 603 *Oncogene* **28**: 63-72
- 604 14. Mo L, Deng FM, Chachoua A, Huang WC, Ma HY, Lepor H, Huang CS, Wu XR (2014) Novel role of X-linked
- 605 inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression.
- 606 *Journal Of Clinical Oncology* **32**:
- 607 15. Yang L, Cao ZH, Yan H, Wood WC (2003) Coexistence of high levels of apoptotic signaling and inhibitor of
- 608 apoptosis proteins in human tumor cells: Implication for cancer specific therapy. *Cancer research* **63**:
- 609 6815-6824
- 610 16. Chai JJ, Shiozaki E, Srinivasula SM, Wu Q, Dataa P, Alnemri ES, Shi YG (2001) Structural basis of caspase-7
- 611 inhibition by XIAP. *Cell* **104**: 769-780

- 612 17. Liu JY, Zhang DY, Luo WJ, Yu JX, Li JX, Yu YH, Zhang XH, Chen JY, Wu XR, Huang CS (2012) E3 Ligase Activity of
613 XIAP RING Domain Is Required for XIAP-Mediated Cancer Cell Migration, but Not for Its RhoGDI Binding Activity.
614 *PLoS one* **7**:
- 615 18. Gyrød-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF- κ B, inflammation
616 and cancer. *Nature Reviews Cancer* **10**: 561-574
- 617 19. Suzuki Y, Nakabayashi Y, Takahashi R (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of
618 apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in
619 Fas-induced cell death. *Proceedings of the National Academy of Sciences of the United States of America* **98**:
620 8662-8667
- 621 20. Cao ZP, Zhang RW, Li JX, Huang HS, Zhang DY, Zhang JJ, Gao JM, Chen JY, Huang CS (2013) X-linked Inhibitor
622 of Apoptosis Protein (XIAP) Regulation of Cyclin D1 Protein Expression and Cancer Cell Anchorage-independent
623 Growth via Its E3 Ligase-mediated Protein Phosphatase 2A/c-Jun Axis. *J Biol Chem* **288**: 20238-20247
- 624 21. Cao ZP, Li XY, Li JX, Luo WJ, Huang CS, Chen JY (2014) X-linked inhibitor of apoptosis protein (XIAP) lacking
625 RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the
626 E2F1/Cyclin E axis. *Oncotarget* **5**: 7126-7137
- 627 22. Huang C, Zeng XR, Jiang GS, Liao X, Liu C, Li JX, Jin HL, Zhu JL, Sun H, Wu XR, *et al.* (2017) XIAP BIR domain
628 suppresses miR-200a expression and subsequently promotes EGFR protein translation and
629 anchorage-independent growth of bladder cancer cell. *J Hematol Oncol* **10**:
- 630 23. Liu JY, Zhang DY, Luo WJ, Yu YH, Yu JX, Li JX, Zhang XH, Zhang BL, Chen JY, Wu XR, *et al.* (2011) X-linked
631 Inhibitor of Apoptosis Protein (XIAP) Mediates Cancer Cell Motility via Rho GDP Dissociation Inhibitor
632 (RhoGDI)-dependent Regulation of the Cytoskeleton. *J Biol Chem* **286**:
- 633 24. Yu JX, Zhang DY, Liu JY, Li JX, Yu YH, Wu XR, Huang CS (2012) RhoGDI SUMOylation at Lys-138 Increases Its
634 Binding Activity to Rho GTPase and Its Inhibiting Cancer Cell Motility. *J Biol Chem* **287**: 13752-13760
- 635 25. Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, Tian Z, Wu XR, Tang MS, *et al.* (2016) XIAP RING domain
636 mediates miR-4295 expression and subsequently inhibiting p63alpha protein translation and promoting
637 transformation of bladder epithelial cells. *Oncotarget*, 10.18632/oncotarget.10645
- 638 26. Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression
639 and their pharmacological targeting. *FEBS J* **278**: 16-27
- 640 27. Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, Li J, Tian Z, Jiang G, *et al.* (2018) XIAP overexpression promotes
641 bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta
642 mRNA stability. **142**: 2040-2055
- 643 28. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA,
644 Theodorescu D (2011) Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling
645 pathway in bladder cancer. *Cancer Res* **71**: 832-841
- 646 29. Chen K, Rajewsky N (2007) The evolution of gene regulation by transcription factors and microRNAs. *Nat*
647 *Rev Genet* **8**: 93-103
- 648 30. Bail S, Swerdel M, Liu H, Jiao X, Goff LA, Hart RP, Kiledjian M (2010) Differential regulation of microRNA
649 stability. *RNA* **16**: 1032-1039
- 650 31. Ruegger S, Grosshans H (2012) MicroRNA turnover: when, how, and why. *Trends in Biochemical Sciences* **37**:
651 436-446
- 652 32. Rossi JJ (2005) Mammalian Dicer finds a partner. *EMBO reports* **6**: 927-929

- 653 33. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM,
654 Fernandez-Piqueras J, Malumbres M (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1
655 and BCR-ABL1 oncogene expression. *Cancer Cell* **13**: 496-506
- 656 34. Huang C, Zeng X, Jiang G, Liao X, Liu C, Li J, Jin H, Zhu J, Sun H, Wu XR, *et al.* (2017) XIAP BIR domain
657 suppresses miR-200a expression and subsequently promotes EGFR protein translation and
658 anchorage-independent growth of bladder cancer cell. *Journal of hematology & oncology* **10**: 6
- 659 35. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM,
660 Sutherland G, *et al.* (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix
661 metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
662 *British journal of cancer* **79**: 1828-1835
- 663 36. Rodriguez Faba O, Palou-Redorta J, Fernandez-Gomez JM, Algaba F, Eiro N, Villavicencio H, Vizoso FJ (2012)
664 Matrix Metalloproteinases and Bladder Cancer: What is New? *ISRN Urol* **2012**: 581539
- 665 37. Woessner JF, Jr. (1998) Role of matrix proteases in processing enamel proteins. *Connective tissue research*
666 **39**: 69-73; discussion 141-149
- 667 38. Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase
668 activity with potential applicability to the entire matrix metalloproteinase gene family. *Proceedings of the*
669 *National Academy of Sciences of the United States of America* **87**: 5578-5582
- 670 39. Cao J, Sato H, Takino T, Seiki M (1995) The C-Terminal Region Of Membrane Type Matrix Metalloproteinase
671 Is a Functional Transmembrane Domain Required for Pro-Gelatinase-C Activation. *J Biol Chem* **270**: 801-805
- 672 40. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F (1993)
673 Levels Of Matrix Metalloproteases In Bladder-Cancer Correlate with Tumor Grade And Invasion. *Cancer*
674 *research* **53**: 5365-5369
- 675 41. Yeatman TJ (2004) A renaissance for SRC. *Nat Rev Cancer* **4**: 470-480
- 676 42. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. *Cancer and*
677 *Metastasis Reviews* **22**: 337-358
- 678 43. Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux JF, Hollande F, Cruzalegui F, Roche S (2010)
679 Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization.
680 *Oncogene* **29**: 1303-1315
- 681 44. Jain S, Shah M, Li P, Wang QF, Zhang SY (2011) Src: A novel target for chemoprevention of early stage ER-
682 breast cancer. *Cancer research* **71**:
- 683 45. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA (1986) Analysis of pp60c-src protein kinase
684 activity in human tumor cell lines and tissues. *J Biol Chem* **261**: 13754-13759
- 685 46. Fanning P, Bulovas K, Saini KS, Libertino JA, Joyce AD, Summerhayes IC (1992) Elevated expression of
686 pp60c-src in low grade human bladder carcinoma. *Cancer research* **52**: 1457-1462
- 687 47. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D (2009) Src phosphorylation
688 of RhoGDI2 regulates its metastasis suppressor function. *Proc Natl Acad Sci U S A* **106**: 5807-5812
- 689 48. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, *et al.*
690 (2007) Micro-RNA profiling in kidney and bladder cancers. *Urol Oncol* **25**: 387-392
- 691 49. Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. *Eur J Cancer* **41**: 2438-2448
- 692 50. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo
693 RM, *et al.* (2006) HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. *Cancer Cell* **9**: 459-471

- 694 51. Zhang YT, Zhu JH, Tang Y, Li F, Zhou HY, Peng BF, Zhou CF, Fu R (2011) X-linked inhibitor of apoptosis positive
695 nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. *Diagnostic*
696 *Pathology* **6**:
- 697 52. Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, Liao X, Li J, Zhang D, Zeng X, *et al.* (2016)
698 Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion
699 In Vitro by Targeting STAT1/FOXO1 Axis. *Cancer Prev Res (Phila)* **9**: 567-580
- 700 53. Jin H, Yu Y, Hu Y, Lu C, Li J, Gu J, Zhang L, Huang H, Zhang D, Wu XR, *et al.* (2015) Divergent behaviors and
701 underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T
702 bladder cancer cell lines. *Oncotarget* **6**: 522-536
- 703 54. Gildea JJ, Golden WL, Harding MA, Theodorescu D (2000) Genetic and phenotypic changes associated with
704 the acquisition of tumorigenicity in human bladder cancer. *Genes Chromosomes Cancer* **27**: 252-263
- 705 55. Jin H, Xie Q, Guo X, Xu J, Wang A, Li J, Zhu J, Wu XR, Huang H, Huang C (2017) p63alpha protein
706 up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9
707 signaling and bladder cancer invasion. *J Biol Chem* **292**: 15952-15963
- 708 56. Liao G, Panettieri RA, Tang DD (2015) MicroRNA-203 negatively regulates c-Abl, ERK1/2 phosphorylation,
709 and proliferation in smooth muscle cells. *Physiol Rep* **3**:
- 710 57. Huang HS, Ma L, Li JX, Yu YH, Zhang DY, Wei JL, Jin HL, Xu DR, Gao JM, Huang CS (2014) NF-kappa B1 inhibits
711 c-Myc protein degradation through suppression of FBW7 expression. *Oncotarget* **5**: 493-505
- 712 58. Xu JW, Wang YL, Hua XH, Xu JH, Tian ZX, Jin HL, Li JX, Wu XR, Huang CS (2016) Inhibition of PHLPP2/cyclin
713 D1 protein translation contributes to the tumor suppressive effect of NF kappa B2 (p100). *Oncotarget* **7**:
714 34112-34130
- 715 59. Wang Y, Xu J, Gao G, Li J, Huang H, Jin H, Zhu J, Che X, Huang C (2016) Tumor-suppressor NF kappa B2 p100
716 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. *Oncogene* **35**: 4080-4090
- 717 60. Yu Y, Zhang D, Huang H, Li J, Zhang M, Wan Y, Gao J, Huang C (2014) NF-kappa B1 p50 promotes p53 protein
718 translation through miR-190 downregulation of PHLPP1. *Oncogene* **33**: 996-1005
- 719 61. Noguchi S, Mori T, Nakagawa T, Itamoto K, Haraguchi T, Mizuno T (2015) DNA methylation contributes
720 toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells. *Melanoma Res* **25**:
721 390-398
- 722

723 **Figure Legends**

724

725 **Figure 1. XIAP BIR domains promoted MMP2 activation and BC invasion.**

726 (A) The schematic structure of XIAP domains. (B and C) The indicated cell extracts were
727 subjected to Western Blot for determination of the expression of XIAP and pro-MMP2 and
728 cleaved-MMP2 (activated-MMP2). β -Actin was used as the protein loading control. (D and
729 E) T24T (Nonsense/Vector), T24T (shXIAP/Vector), T24T (shXIAP/ Δ RING) cells were
730 cultured in uncoated chambers or pre-coated Matrigel chambers for 24 hours. The cells were
731 then fixed and stained. The invasion and migration rates were quantified by counting the
732 relative migratory (Transwell) and invasive cells in at least five random fields under a light
733 microscope, and then, the cell numbers were normalized with the insert control according to
734 the manufacturer's instructions. The bars show the mean \pm SD of 3 independent experiments.
735 The symbol (*) indicates a significant difference as compared with the vehicle control ($p <$
736 0.05), and the symbol (\clubsuit) indicates a significant difference compared with T24T
737 (shXIAP/Vector) cells ($p <$ 0.05).

738

739 **Figure 2. Src downregulation by XIAP BIR domains resulted in BC invasion in human**
740 **BCs.**

741 (A) The indicated cell extracts were subjected to Western blot for determination of Src
742 expression. (B and C) Total RNA and protein lysates were prepared from human normal and
743 the paired human bladder urothelial cell mixtures separately from 20 patients diagnosed with
744 bladder cancer and subjected to qRT-PCR and Western blotting analyses to determine Src
745 mRNA (B) and protein (C) expression profiles, respectively. (Non-S.P: Non-Specific Protein)
746 (D and E) IHC-P was carried out to evaluate Src protein expression in mouse BC induced
747 through consistent exposure of mice to BBN for 20 weeks. The optical density was analyzed
748 as described in "materials and methods". The symbol (*) indicates a significant decrease in
749 comparison to normal mice ($p <$ 0.01). (F and G) The cell extracts from the indicated stable
750 transfectants were subjected to Western Bot for determination of related protein expression.

751 **(H-K)** The indicated stably transfectants were subjected to cell migration and invasion assays
752 as described in “materials and methods”.

753

754 **Figure 3. BIR domains of XIAP promoted miR-203 transcription and in turn inhibited**
755 **Src tyrosine kinase protein translation in human bladder cancer cells.**

756 **(A)** Total RNA was isolated from the indicated cells and then subjected to RT-PCR analysis
757 of src mRNA expression. GAPDH was used as a loading control. **(B)** After pre-treatment
758 with MG132 (10 μ M) for 6 h, T24T (Nonsense) and T24T (shXIAP) cells were subjected to
759 determination of Src protein degradation in the presence of cycloheximide (CHX) (100
760 μ g/ml). β -Actin was used as a protein loading control. **(C)** After pretreatment with MG132
761 (10 μ M) for 30 mins, newly synthesized Src protein in T24T (Nonsense) and T24T (shXIAP)
762 cells was monitored with a pulse assay using 35 S-labeled methionine/cysteine. WCL stands
763 for whole cell lysate. Coomassie blue staining was used for protein loading control. **(D)** The
764 cell extracts were subjected to Western Blot as indicated. β -Actin was used as a loading
765 control. **(E)** The indicated cells were transiently transfected with a Src 3'UTR luciferase
766 reporter and the luciferase activity of each transfectant was evaluated. The results are
767 presented as Src 3'-UTR activity relative to medium control. The symbol (*) indicates a
768 significant increase as compared with T24T (Nonsense/Vector) ($p < 0.01$). The symbol (\star)
769 indicates a significant decrease as compared with T24T (shXIAP/Vector) cells. **(F)** The levels
770 of the indicated microRNAs were evaluated with quantitative real-time PCR. The symbol (*)
771 indicates a significant decrease compared with control cells as indicated ($p < 0.01$). **(G)** The
772 level of miR-203 in the indicated cells was evaluated with quantitative real-time PCR. The
773 symbol (*) indicates a significant decrease as compared with nonsense cells as indicated ($p <$
774 0.01), while the symbol (\star) indicates a significant increase as compared with T24T
775 (shXIAP/Vector) cells. **(H)** Schematic of the construction of the src mRNA 3'-UTR luciferase
776 reporter and its mutants aligned with miR-203. **(I and J)** T24T (Nonsense), T24T (shXIAP)
777 cells and T24T (shXIAP/Vector), T24T (shXIAP/ Δ RING) cells were co-transfected with
778 wild-type and mutant src 3'-UTR luciferase reporters and pRL-TK, respectively. The

779 luciferase activity of each transfectant was evaluated, and the results are presented as relative
780 to src 3'-UTR activity. The symbol (*) indicates a significant difference in src 3'-UTR activity
781 ($p < 0.01$). **(K)** T24T (shXIAP/Vector) and UMUC3 (shXIAP/Vector) cells were stably
782 transfected with constructs of miR-203 or its control vector. miR-203 expression was
783 determined with real-time PCR, and the symbol (*) indicates a significant increase as
784 compared with control nonsense transfectant ($p < 0.05$). **(L and M)** The indicated cell
785 extracts were subjected to Western blotting, and β -Actin was used as the protein loading
786 control.

787

788 **Figure 4. XIAP BIR domains promote miR-203 transcription through transactivation of**
789 **E2F1 and Sp1 in human BC cells.**

790 **(A)** The indicated cells were incubated with actinomycin D (20 μ g/ml) for the indicated time
791 periods. Total RNA was isolated, and quantitative real-time PCR was then performed to
792 determine miR-203 levels. The fold change was normalized using GAPDH as the internal
793 control. **(B)** The relative expression levels of pre-miR203 were evaluated with quantitative
794 real-time PCR in the indicated cells. **(C)** The indicated cells were stably transfected with a
795 miR-203 promoter-driven luciferase reporter to determine the miR-203 promoter
796 transcriptional activity. **(D)** XIAP and its BIR domains did not affect miR-203 promoter
797 methylation. **(E)** Schematic representation of the transcription factor binding sites in the
798 human miR-203 promoter-driven luciferase reporter. **(F)** The indicated cell extracts were
799 subjected to Western blot to determinate the functional transcription factors, and GAPDH was
800 used as a protein loading control. **(G and H)** T24T (Nonsense), T24T (shXIAP/Vector), and
801 T24T (shXIAP/ Δ RING) cells were transfected with an Sp1-dependent luciferase reporter (G)
802 or an E2F1-dependent luciferase reporter (H), together with pRL-TK. The results are
803 presented as luciferase activity relative to that of vector control transfectants. **(I)** ChIP assay
804 was performed using anti-E2F1 or anti-Sp1 antibody to detect the interaction between E2F1
805 or Sp1 and the miR-203 promoter. **(J and K)** T24T and UMUC3 cells stably transfected with
806 E2F1 overexpression construct, and the stable transfectants were identified and determined

807 Sp1 expression (J). (K) The stable transfectants were subjected to evaluate the level of
808 miR-203 with real-time PCR, and the symbol (*) indicates a significant increase in miR-203
809 expression in E2F1 overexpression cells compared with vector transfectants ($p < 0.01$). (L
810 and M) T24T cells were stably transfected with two Sp1 knockdown plasmids separately,
811 and Western blot was employed to determine Sp1 protein expression, and Real-time PCR was
812 performed to determine the miR-203 expression in the stable Sp1 knockdown cells. (N) The
813 stable E2F1 overexpression BC cells were stably transfected with a miR-203 promoter-driven
814 luciferase reporter to determine the miR-203 promoter transcriptional activity. (O) The stable
815 Sp1 knockdown cells were stably transfected with a miR-203 promoter-driven luciferase
816 reporter to determine the miR-203 promoter transcriptional activity.

817

818 **Figure 5. Sp1 is crucial for XIAP BIR domains-mediated E2F1 transcription and**
819 **promoting BC cell invasion.**

820 (A) RT-PCR was performed to determine the e2f1 mRNA levels in the indicated cells. (B)
821 T24T (Nonsense), T24T (shXIAP/Vector), and T24T (shXIAP/ Δ RING) cells were
822 co-transfected with an E2F1 promoter-driven luciferase reporter together with pRL-TK. Then,
823 24 hours post transfection, the transfectants were extracted to evaluate luciferase activity,
824 with normalization to TK. The results were presented as luciferase activity relative to
825 scramble nonsense transfectant. Each bar indicates the mean \pm SD of three independent
826 experiments. The symbol (*) and (\clubsuit) indicates a significant difference as compared with the
827 vehicle control and T24T (shXIAP/vector), separately ($p < 0.05$). (C) The stable Sp1
828 knockdown cells were stably transfected with E2F1 promoter-driven luciferase reporter to
829 determine the E2F1 promoter transcriptional activity. (D) The potential transcription factor
830 binding sites in the e2f1 promoter. (E-H) Different type of transfectants were subjected to
831 cell invasion and migration assays with transwell invasion assay system (E and G). The
832 migration and invasion rates were normalized with the insert control according to the
833 manufacturer's instructions, and the results are presented as the number of migratory or
834 invasive cells relative to vector control transfectants (F and H).

835

836 **Figure 6. BIR2 and BIR3 domains of XIAP differentially interacted with Sp1 and E2F1**
837 **and promote BC invasion.**

838 (A) Immunoblotting analysis of whole-cell lysates (Input) and GFP-immunoprecipitates (IP)
839 obtained from T24T cells transfected with HA-XIAP with or without combination with
840 GFP-Sp1 using anti-GFP and anti-E2F1 antibody-conjugated beads. (B) Immunoblotting
841 analysis of whole-cell lysates (Input) and HA-immunoprecipitates (IP) obtained from T24T
842 cells transfected with GFP-Sp1 alone or in combination with HA-XIAP using anti-HA and
843 anti-E2F1 antibody-conjugated beads. (C) Total cellular protein was extracted from the
844 indicated cells, and a co-immunoprecipitation assay was performed using anti-HA
845 antibody-conjugated beads. Immunoprecipitated protein was then subjected to Western
846 blotting to detect the interaction of XIAP BIR domains with antibodies as indicated. (D)
847 Immunoblotting analysis of whole-cell lysates (Input) and HA-immunoprecipitates (IP)
848 obtained from T24T cells transfected with GFP-Sp1 with or without combination with
849 various XIAP fragments using anti-HA antibody-conjugated beads. (E) Immunoblotting
850 analysis of whole-cell lysates and anti-HA-immunoprecipitates (IP) obtained from
851 T24T(HA-XAP) cells following synchronization overnight in 0.1% fetal bovine serum (FBS)
852 medium and further stimulation with 20% FBS medium for 30 min. (F) Immunoblotting
853 analysis of cytoplasmic and nuclear fractions of T24T cells following 24 h of serum
854 deprivation and further stimulation with 20% FBS for 30 min. β -Actin and poly-(ADP-ribose)
855 polymerase (PARP) are cytoplasmic and nuclear markers, respectively. (G) The indicated cell
856 extracts were subjected to Western blotting for determination of the expression of XIAP,
857 E2F1, Src and pro-MMP2 and cleaved-MMP2 (activated-MMP2). β -Actin was used as the
858 protein loading control. (H-I) Different types of transfectant were subjected to cell invasion
859 and migration assay by using transwell invasion assay system (H). The migration and
860 invasion rates were normalized with the insert control according to the manufacturer's
861 instructions, and the symbol (*) and (♣) indicates a significant difference compared with the
862 vehicle control and T24T (shXIAP/vector), separately ($p < 0.05$) (I). (J and K) T24T

863 (Nonsense), T24T (shXIAP/Vector), T24T (shXIAP/BIR1), T24T (shXIAP/BIR2) and T24T
864 (shXIAP/BIR3) cells were transfected with an E2F1-dependent luciferase reporter (J) or a
865 Sp1-dependent luciferase reporter (K), together with pRL-TK. The results are presented as
866 luciferase activity relative to that of vector control transfectants. (L) The indicated cells were
867 stably transfected with a miR-203 promoter-driven luciferase reporter to determine the
868 miR-203 promoter transcriptional activity. The symbol (*) indicates a significant decrease as
869 compared with nonsense cells as indicated ($p < 0.01$), while the symbol (♣) indicates a
870 significant increase as compared with T24T (shXIAP/Vector) cells. (M) The level of miR-203
871 in the indicated cells was evaluated with quantitative real-time PCR. (N) The schematic of the
872 potential XIAP BIR domains- and RING domain-mediated regulation of bladder cancer
873 promotion, and invasion.


Figure 1

Figure 2




Figure 3





Figure 4

Figure 5




Figure 6




Figure 6





Table 1: The potential miRNAs binding sites in the Src mRNA 3'UTR region

Position 1867-1873 of SRC 3' UTR hsa-miR-141-3p	5' ...UUUUUUUUUUUUUAACAGUGUUU... 3' GGUAGAAAUGGUCUGUCACAAU
Position 1843-1849 of SRC 3' UTR hsa-miR-144-3p	5' ...GUGUAAGGUGUCUAAUACUGUC... 3' UCAUGUAGUAGAU AUGACAU
Position 1620-1627 of SRC 3' UTR hsa-miR-137	5' ...UGGCCCCUCAUCAUAGCAAUAA... 3' GAUGC GCAUAAGAAUUCGUUAUU
Position 1594-1601 of SRC 3' UTR hsa-miR-203-3p	5' ...CCCCAAACAUGUUGUACA UUUUCA... 3' GAUCACCAGGAUUUGUAAAGU
Position 1867-1873 of SRC 3' UTR hsa-miR-200a-3p	5' ...UUUUUUUUUUUUUAACAGUGUUU... 3' UGUAGCAAUGGUCUGUCACAAU
Position 1756-1762 of SRC 3' UTR hsa-miR-206	5' ...AAGUCUUCUCCCGUCCA UUCCAG... 3' GGUGUGUGAAGGAAU-----GUAAGGU